Artivion, Inc. (NYSE:AORT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Artivion, Inc. (NYSE:AORT) has been assigned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $49.1143.

AORT has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, October 8th. Canaccord Genuity Group reiterated a “buy” rating and set a $51.00 price objective on shares of Artivion in a research note on Wednesday, December 17th. Citizens Jmp boosted their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Wall Street Zen raised Artivion from a “buy” rating to a “strong-buy” rating in a research report on Sunday, December 21st. Finally, Needham & Company LLC increased their target price on shares of Artivion from $50.00 to $58.00 and gave the stock a “buy” rating in a report on Friday, November 7th.

Artivion Trading Up 0.2%

AORT opened at $43.36 on Monday. Artivion has a one year low of $21.97 and a one year high of $48.25. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.93 and a quick ratio of 2.88. The business has a 50 day simple moving average of $45.39 and a two-hundred day simple moving average of $41.53. The firm has a market capitalization of $2.05 billion, a price-to-earnings ratio of -180.65 and a beta of 1.59.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. The firm had revenue of $113.39 million for the quarter, compared to analyst estimates of $110.71 million. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.Artivion’s quarterly revenue was up 18.9% on a year-over-year basis. Analysts predict that Artivion will post 0.37 EPS for the current year.

Insider Buying and Selling

In related news, CEO James P. Mackin sold 30,921 shares of the company’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $45.56, for a total transaction of $1,408,760.76. Following the sale, the chief executive officer owned 800,993 shares of the company’s stock, valued at $36,493,241.08. This represents a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Amy Horton sold 4,572 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $44.42, for a total value of $203,088.24. Following the sale, the chief accounting officer directly owned 130,058 shares in the company, valued at $5,777,176.36. The trade was a 3.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 234,511 shares of company stock valued at $10,612,452 in the last three months. Corporate insiders own 7.60% of the company’s stock.

Institutional Trading of Artivion

Several institutional investors have recently added to or reduced their stakes in AORT. Verition Fund Management LLC grew its stake in shares of Artivion by 1.6% during the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock valued at $716,000 after buying an additional 274 shares during the last quarter. State of Alaska Department of Revenue boosted its holdings in Artivion by 1.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 23,294 shares of the company’s stock valued at $985,000 after acquiring an additional 414 shares during the period. PNC Financial Services Group Inc. grew its position in Artivion by 6.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock valued at $349,000 after acquiring an additional 477 shares during the last quarter. Van ECK Associates Corp grew its position in Artivion by 19.0% in the 3rd quarter. Van ECK Associates Corp now owns 3,176 shares of the company’s stock valued at $134,000 after acquiring an additional 506 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund increased its stake in Artivion by 5.8% in the third quarter. Oregon Public Employees Retirement Fund now owns 9,329 shares of the company’s stock worth $395,000 after purchasing an additional 510 shares during the period. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.